Inhibitory Effect And Mechanism Of Anlotinib Combined With Paclitaxel On ECA109 Cells Of Esophageal Cancer

Objective:To investigate the effect of anlotinib on the proliferation,invasion and apoptosis of esophageal cancer ECA-109 cells by targeting vascular endothelial growth factor receptor 2（VEGFR2）.Methods:The expression of VEGFR2 in esophageal squamous cell carcinoma and its relationship with clinicopathological features were detected by immunohistochemistry.CCK8,flow cytometry,apoptosis test,cell cycle test and Transwell test were used to detect the effects of anlotinib,anlotinib combined with paclitaxel on the proliferation,apoptosis,cycle and migration of ECA-109 cells;The expressions of VEGFR2,p-m TOR,p-AKT,pVEGFR2,Bcl-2,Bax and active caspase-3 were detected by Western blot.Results:VEGFR2 was highly expressed in clinical specimens of patients with esophageal squamous cell carcinoma and was related to lymph node metastasis and TNM stage（P <0.05）.Anlotinib combined with paclitaxel significantly inhibited the proliferation and migration of Eca-109 cells and promoted apoptosis compared with anlotinib alone The results of Western blotting showed that VEGFR2,p-m TOR,p-AKT,p-VEGFR2,Bcl-2decreased and Bax,Active Caspase-3 increased.Conclusions:VEGFR2 is highly expressed in clinical specimens of patients with esophageal squamous cell carcinoma and is related to lymphatic metastasis and TNM stage.It is an indicator of poor prognosis.Anlotinib combined with paclitaxel inhibited the proliferation and migration of ECA-109 cells and promoted apoptosis.Anlotinib combined with paclitaxel may play an anti-cancer role by targeting VEGFR2/AKT/m TOR signaling pathway,which provides a theoretical basis for the treatment of esophageal cancer.